# Genentech, Inc. clinical trials: 517 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 517 trials with Genentech, Inc. as lead sponsor, 18 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genentech, Inc.: 517 rows for $25.85, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/genentech-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 517
- Recruiting or not yet: 18
- Read on: November 19, 2026

## Trials

The 25 newest of 517, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 9, 2026 | NCT07867262 | A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally... | Genentech, Inc. | Phase 1 | Not yet recruiting | Advanced or Metastatic Breast Cancer | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867262) |
| October 5, 2026 | NCT07859085 | A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable... | Genentech, Inc. | Phase 1 | Not yet recruiting | Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | 388 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859085) |
| October 1, 2026 | NCT07851259 | A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Genentech, Inc. | Phase 2 | Recruiting | Geographic Atrophy Secondary to Age-Related Macular Degeneration | 321 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851259) |
| September 1, 2026 | NCT07797478 | A Study of RO7890597 in Healthy Adult Volunteers | Genentech, Inc. | Phase 1 | Recruiting | Healthy Volunteers | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797478) |
| August 24, 2026 | NCT07783009 | An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small... | Genentech, Inc. | Not applicable | Available | Non-Small Cell Lung Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783009) |
| June 12, 2026 | NCT07643831 | Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer | Genentech, Inc. | Not applicable | Available | ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643831) |
| June 5, 2026 | NCT07629583 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Genentech, Inc. | Phase 1 | Recruiting | Lupus Erythematosus, Systemic | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629583) |
| May 27, 2026 | NCT07609719 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | Genentech, Inc. | Phase 4 | Recruiting | Multiple Sclerosis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609719) |
| May 5, 2026 | NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate... | Genentech, Inc. | Phase 1/2 | Recruiting | Advanced Prostate Cancer, Metastatic Prostate Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567846) |
| April 30, 2026 | NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Genentech, Inc. | Phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558915) |
| April 21, 2026 | NCT07541079 | A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast... | Genentech, Inc. | Phase 3 | Recruiting | Early Breast Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541079) |
| March 4, 2026 | NCT07448038 | A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation... | Genentech, Inc. | Phase 2 | Recruiting | Atherosclerosis | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448038) |
| February 23, 2026 | NCT07425522 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular... | Genentech, Inc. | Phase 1 | Recruiting | Diabetic Macular Edema | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425522) |
| January 15, 2026 | NCT07342114 | A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With... | Genentech, Inc. | Phase 1 | Active not recruiting | Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342114) |
| January 9, 2026 | NCT07329972 | A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants | Genentech, Inc. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07329972) |
| October 9, 2025 | NCT07214766 | A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants | Genentech, Inc. | Phase 1 | Completed | Healthy Participants | 331 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214766) |
| October 9, 2025 | NCT07214662 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in... | Genentech, Inc. | Phase 1 | Terminated | Breast Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214662) |
| August 27, 2025 | NCT07144111 | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | Genentech, Inc. | Phase 1 | Completed | Hepatic Impairment | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144111) |
| August 3, 2025 | NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants... | Genentech, Inc. | Phase 1/2 | Recruiting | Breast Cancer | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07100106) |
| July 4, 2025 | NCT07051993 | A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and... | Genentech, Inc. | Phase 1 | Completed | Healthy Participants | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07051993) |
| June 17, 2025 | NCT07025577 | A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions | Genentech, Inc. | Phase 1 | Completed | Healthy Participants | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025577) |
| June 6, 2025 | NCT07008378 | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple... | Genentech, Inc. | Phase 1 | Active not recruiting | Multiple Sclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07008378) |
| May 22, 2025 | NCT06984341 | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With... | Genentech, Inc. | Phase 1 | Withdrawn | Systemic Lupus Erythematosus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06984341) |
| May 18, 2025 | NCT06979336 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active... | Genentech, Inc. | Phase 2 | Recruiting | Ulcerative Colitis | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06979336) |
| February 28, 2025 | NCT06850922 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With... | Genentech, Inc. | Phase 1/2 | Completed | Diabetic Macular Edema | 388 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06850922) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 211 |
| Phase 1/2 | 15 |
| Phase 2 | 148 |
| Phase 2/3 | 3 |
| Phase 3 | 68 |
| Phase 4 | 25 |
| Not applicable | 14 |
| Observational | 33 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 404 |
| Terminated | 51 |
| Active not recruiting | 22 |
| Recruiting | 16 |
| Withdrawn | 9 |
| Approved for marketing | 6 |
| No longer available | 3 |
| Not yet recruiting | 2 |
| Available | 2 |
| Unknown | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 45 |
| Carcinoma, Non-Small-Cell Lung | 30 |
| Colorectal Neoplasms | 25 |
| Neoplasms | 23 |
| Arthritis, Rheumatoid | 21 |
| Asthma | 20 |
| Lymphoma, Non-Hodgkin | 18 |
| Multiple Myeloma | 14 |
| Macular Degeneration | 13 |
| Ovarian Neoplasms | 13 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 |
| Alzheimer Disease | 12 |
| Lung Neoplasms | 10 |
| Melanoma | 10 |
| Lupus Erythematosus, Systemic | 10 |
| Psoriasis | 10 |
| Geographic Atrophy | 8 |
| Colitis, Ulcerative | 8 |
| Neoplasm Metastasis | 8 |
| Macular Edema | 7 |
| Idiopathic Pulmonary Fibrosis | 7 |
| Multiple Sclerosis | 7 |
| Carcinoma, Renal Cell | 6 |
| Carcinoma, Basal Cell | 6 |
| Chronic Urticaria | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [B2B oil and gas equipment companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-equipment-companies/united-states)
- [Pediatric dentistry practices in the United States](https://specstream.ai/data/businesses/pediatric-dentistry-practices/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
